Reading this on Krawl? Register for free.
Unlock listen-aloud, reading history and personalised feeds — at zero cost.
Free registration unlocks the full Finance Desk
Chinese Biotech Evolves from Licensing to Strategic Global Partnerships
Chinese biotech firms are advancing beyond simple out-licensing agreements toward deeper strategic collaborations, reflecting a shift from replication to differentiated innovation. The trend is evident in deals like InnoCare Pharma's significant…
Shifting Deal Structures in Chinese Biotech
Chinese biotech deal structures are evolving beyond one-off drug candidate licensing, signaling the country's transition from a technology adopter to a global innovation leader, according to financial analysts. This shift became evident with Beijing-based InnoCare Pharma's strategic research and licensing agreement with Eli Lilly, announced on Thursday, potentially valued at up to $3.35 billion.
InnoCare specified its role in leveraging its drug discovery platform to identify and advance compounds for as many as five targets. While specific therapeutic areas remained undisclosed, both companies indicated a focus on developing new drugs to address critical unmet medical needs.
Cui Cui, head of Asia healthcare research at Jefferies, noted in a research brief that China's biotech sector has moved past a “speed-driven replication” model towards “differentiated innovation.” This transition is expected to spur more globally significant drug development partnerships originating from China, a sentiment reinforced by private discussions at Jefferies' recent APAC Healthcare Conference in Shanghai.
From Out-licensing to Co-development
Many Chinese biotech companies initially relied on out-licensing, a model where an early-stage drug candidate's rights are sold to another firm for global development and commercialization, to finance their research pipelines. However, as these companies expanded their resources and ambitions, they increasingly adopted co-development agreements and broader platform partnerships, Cui explained.
Under the terms of the InnoCare agreement, Eli Lilly will provide an upfront payment of $100 million. InnoCare stands to receive up to $3.25 billion in milestone payments tied to development and commercialization, along with single-digit tiered royalties on annual net product sales, as stated in their Thursday announcement.
Other recent agreements further illustrate this broadening approach to global deal-making. Jiangsu Hengrui Pharmaceutical, China's largest drug maker by market capitalization, entered a collaboration and licensing agreement with Bristol Myers Squibb (BMS) worth up to $15.2 billion. This deal saw BMS commit $600 million in upfront payments in May to advance 13 early-stage programs across oncology, hematology, and immunology, with five assets slated for joint development using Hengrui's discovery platforms.
Rising Quality of Chinese Drug Research
Jialin Zhang, Nomura's head of China healthcare research, highlighted in a Wednesday report the increasing impact of Chinese research in global forums. Chinese contributions accounted for 29 of the 96 late-breaking abstracts scheduled for presentation at the European Society for Medical Oncology (Esmo) Congress 2026 in Madrid, including five of the twelve studies selected for the prestigious presidential symposium. Zhang commented that these figures reflect the “rising quantity and quality of China’s innovative drug research.”
Found this useful? Share it!
Interested in Finance Education?
Explore our CFA and investing courses — built for serious learners.
